Dr. Carmelo Carlo-Stella received his medical degree cum Laude from the University of Pavia (1981), where he also obtained a specialization in Internal Medicine (1986). He trained in cellular and molecular hematology at the Department of Hematology, University of Frankfurt (1985, 1988). After obtaining a specialization in Hematology at the University of Parma, he joined the National Cancer Institute in Milano (1999-2011), where he served as a member of the active staff in Onco-Hematology, and Director of the Hematopoietic Stem Cell Transplantation Laboratory. From 2006 to 2016, he served as Associate Professor of Medical Oncology at the University of Milano. In 2011, he joined Humanitas Research Hospital in Milano.
Translational and Clinical Research
He has a robust translational research interest in refractory lymphoma with a specific focus on the clinical use of circulating tumor DNA sequencing for the management of lymphoma, and the use of multi-omics approaches to identify signatures of response or resistance to immunotherapy in refractory Diffuse Large B-Cell Lymphoma.
He has served as principal investigator in phase 1/2 clinical trials to develop novel forms of antibody-based immunotherapy and has led registration trials for several novel antibodies (drug-conjugated, bispecifics) for refractory lymphoma.
Publications
Dr. Carlo-Stella (ORCID ID: 0000-0003-3144-0124) has published hundreds of original papers and reviews in leading peer-reviewed journals, including Blood, New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, Cancer Research, Clinical Cancer Research, Leukemia, Bone Marrow Transplantation, and the British Journal of Hematology. As of Jul 20, 2023, scientific publications include ≥250 peer-reviewed articles in journals covered by the JCR®. H-index (Google Scholar) is 51.